Search clinical trials for: PF-02341066/PF-00299804

Total 1293 results

Seoul National University Hospital
Pfizer

Completed

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer (PF299804-AGC)

Advanced Gastric Cancer | HER2

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University Health Network, Toronto
Pfizer

Completed

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Oral Cavity Cancer

Canada
University Health Network, Toronto
Pfizer

Completed

A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Canada
Pfizer

Terminated

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Non-Small Cell Lung Cancer (NSCLC)

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Pfizer

Completed

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Head and Neck Neoplasms

Canada
Pfizer

Completed

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Neoplasms

United States, Netherlands
Yonsei University

Completed

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Head Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell Metastatic

Korea, Republic of
Pfizer

Completed

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

Neoplasms

Japan
NCIC Clinical Trials Group
Pfizer

Completed

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Lung Cancer

Taiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Pfizer

Completed

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis (HER-Uro01)

Carcinoma, Squamous Cell | Penile Neoplasms

Italy
Pfizer

Completed

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Carcinoma, Non-small Cell

United States, Taiwan, Korea, Republic of, Japan, Hong Kong
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Skin Squamous Cell Cancer

Italy
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
National Cancer Institute (NCI)

Terminated

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Carcinoma, Non-Small Cell Lung | Carcinoma, Large Cell

United States
Pfizer

Completed

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Carcinoma, Non Small Cell Lung

United States
Pfizer

Completed

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Australia
Massachusetts General Hospital
Pfizer; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Henry Ford...

Completed

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

Glioblastoma | Glioblastoma Multiforme | GBM

United States
Children's Oncology Group
National Cancer Institute (NCI); Pfizer

Completed

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Childhood Anaplastic Large Cell Lymphoma

United States, Canada
Pfizer

Completed

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Carcinoma, Non Small Cell Lung

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Glioblastoma | Brain Tumor, Recurrent

Spain
Pfizer
Roswell Park Cancer Institute; South Texas Accelerated Research Therapeutics...

Completed

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Advanced Malignant Solid Tumors

United States
University Health Network, Toronto

Completed

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | BRAF Gene Mutation

United States
Pfizer

Terminated

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Non-Small Cell Lung Cancer

United States, Australia, Japan, Korea, Republic of, Spain
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

Healthy

Japan
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Neoplasm Metastasis | Carcinoma, Non-Small Cell

United States, France, Spain
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States
Pfizer

Completed

Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers

Healthy Volunteer

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
European Organisation for Research and Treatment...
Pfizer

Completed

CREATE: Cross-tumoral Phase 2 With Crizotinib (CREATE)

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditions

France, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
Pfizer

Completed

Relative Drug Exposures Of Two Formulations of PF-02341066

Healthy

United States
Pfizer

Completed

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Healthy

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Rottapharm Spain

Completed

Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk

Parkinson's Disease, Idiopathic

Spain

Search clinical trials for: PF-02341066/PF-00299804

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations